Cardinal Health (CAH)
(Delayed Data from NYSE)
$98.70 USD
+1.59 (1.64%)
Updated May 16, 2024 03:59 PM ET
After-Market: $98.72 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.70 USD
+1.59 (1.64%)
Updated May 16, 2024 03:59 PM ET
After-Market: $98.72 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Zacks News
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
by Zacks Equity Research
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
Abbott (ABT) Receives FDA's Approval for the TriClip TEER System
by Zacks Equity Research
Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval
by Zacks Equity Research
Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.
Henry Schein (HSIC) Buys TriMed to Expand in Orthopedic Space
by Zacks Equity Research
According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.
QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches
by Zacks Equity Research
QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.
Why Cardinal (CAH) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GE HealthCare's (GEHC) New Launch to Enhance Cardiac Care
by Zacks Equity Research
GE HealthCare's (GEHC) latest offering is likely to expand access to cardiac care by enabling more medical professionals to be able to capture cardiac images.
Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS
by Zacks Equity Research
Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.
Reasons to Add Cardinal Health (CAH) to Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on research and development raises optimism about the stock.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Globus Medical (GMED) Gains From New Launches Amid Macro Issues
by Zacks Equity Research
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Align (ALGN) Debuts Invisalign Palatal Expander in New Markets
by Zacks Equity Research
Align's (ALGN) Invisalign Palatal Expander system is now available in Australia and New Zealand for skeletal and dental expansion in growing patients.
Veeva Systems (VEEV) Makes Change to Front Office (revised)
by Zacks Equity Research
Veeva Systems' (VEEV) CFO Brent Bowman steps down, leading analysts to weigh in on the impact and prospects for the cloud-solutions company.
Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs
by Zacks Equity Research
Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.
QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing
by Zacks Equity Research
QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
by Zacks Equity Research
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Veeva Systems' (VEEV) CFO Resignation Sparks 6% Stock Drop
by Zacks Equity Research
Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
by Zacks Equity Research
Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.